DGS Capital Management LLC Grows Stock Position in Sanofi (NASDAQ:SNY)

DGS Capital Management LLC boosted its position in Sanofi (NASDAQ:SNY) by 4.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 9,623 shares of the company’s stock after acquiring an additional 385 shares during the period. DGS Capital Management LLC’s holdings in Sanofi were worth $555,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Logan Capital Management Inc. raised its stake in shares of Sanofi by 4.6% during the 3rd quarter. Logan Capital Management Inc. now owns 85,189 shares of the company’s stock valued at $4,909,000 after purchasing an additional 3,774 shares during the period. Franklin Resources Inc. grew its holdings in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after buying an additional 395,744 shares in the last quarter. Tidal Investments LLC increased its position in shares of Sanofi by 126.7% during the third quarter. Tidal Investments LLC now owns 13,798 shares of the company’s stock valued at $795,000 after buying an additional 7,711 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Sanofi in the third quarter worth about $219,000. Finally, World Investment Advisors LLC boosted its position in shares of Sanofi by 1,020.5% in the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company’s stock valued at $2,791,000 after acquiring an additional 44,108 shares during the period. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $46.80 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm’s fifty day moving average price is $51.02 and its 200-day moving average price is $52.04. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a market cap of $118.77 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 1.24 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the business posted $2.55 EPS. Sanofi’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts expect that Sanofi will post 4.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the subject of several analyst reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.